Dr. Rohit Jain on factors affecting treatment selection in renal cell carcinoma

Rohit Jain, MD, Moffitt Cancer Center, discusses risk status and other factors he considers in treatment selection for patients with advanced renal cell carcinoma (RCC).

Note: this interview was filmed before the FDA approval of pembrolizumab plus lenvatinib for the first-line treatment of adult patients with advanced RCC.